Evidence map›Paper›PMID 8529284›Full record

ArticleCancer chemotherapy and pharmacology1996

Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines.

Q Dong, N Bullock, F Ali-Osman, O M Colvin, D D Bigner, H S Friedman

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer chemotherapy and pharmacology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Q DongDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
N Bullock
F Ali-Osman
O M Colvin
D D Bigner
H S Friedman
Duke University Hospital · USDuke University · USJohns Hopkins Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

BRAIN TUMORS: IMMUNOLOGICAL AND BIOLOGICAL STUDIESR37CA011898 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 1988 to 2012
$8.1M
Temodar Resistance in CNS TumorsR01NS030245 · NINDS · DUKE UNIVERSITY · PI FRIEDMAN, HENRY S. · 1992 to 2008
$2.6M
BRAIN TUMORS: IMMUNOLOGICAL AND BIOLOGICAL STUDIESR01CA011898 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 1985 to 1987
–
INTRATHECAL THERAPY OF MELANOMA NEOPLASTIC MENINGITISR01CA056115 · NCI · DUKE UNIVERSITY · PI BIGNER, DARELL D · 1991 to 1993
–
NCI NIH HHS CA 11898NCI NIH HHS CA 56115NINDS NIH HHS NS 30245
6 · The paper itself

Abstract

Cyclophosphamide is one of the most active agents in the treatment of medulloblastoma. However, development of resistance to this alkylator frequently occurs and is the harbinger of tumor progression and death. In order to understand the biochemical basis of this resistance, we generated a panel of medulloblastoma cell lines in our laboratory that were resistant to 4-hydroperoxycyclophosphamide (4-HC). Previously, we have shown that elevated levels of aldehyde dehydrogenase and glutathione mediate cellular resistance to 4-HC. The present study was conducted to identify the third unknown mechanism mediating the resistance of cell line D283 Med (4-HCR) to 4-HC, testing the hypothesis that this resistance is mediated by an increased repair of DNA interstrand crosslinks (ICLs). The doses of 4-HC that produced a one- and two-log cell kill of D283 Med cells were 25 and 50 microM, respectively, compared with values of 125 and 165 microM in D283 Med (4-HCR), the resistant cell line. The formation and disappearance of 4-HC-induced DNA ICLs at the c-myc gene were subsequently studied by DNA denaturing/renaturing gel electrophoresis and Southern blot analysis. 4-HC-induced DNA ICLs in the c-myc gene exhibited a dose-dependent relationship. The percentage of the c-myc gene that was crosslinked was approximately 1-3% at a dose of 100 microM. More than 50% of the DNA crosslinking in D283 Med (4-HCR) cells was removed by 6 h after drug treatment, whereas, in D283 Med cells, more than 90% of the DNA crosslinking was still present at 6 h. These findings suggest that the increased repair of DNA ICLs in D283 Med (4-HCR) may contribute significantly to its resistance to 4-HC.

Indexed as

Blotting, SouthernCross-Linking ReagentsCyclophosphamideDNA, NeoplasmDrug Resistance, NeoplasmElectrophoresisGenes, mycHumansMedulloblastomaTumor Cells, CulturedCross-Linking ReagentsCyclophosphamideDNA, Neoplasmperfosfamide

Identifiers

PMID8529284
OpenAlexW2029881378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.